|
Offer
From Non Premium Member |
|
|
|
Type: |
Sell |
| Subject: |
sell Imatinib Mesylate&sunitinib malate&Emtricitabine |
| Description: |
We,Pharma Department OF Shanghai Richem International Co. LTD. is one of the leading suppliers in Chinese pharmaceutical market.We are specialized in developing, manufacturing and marketing pharmaceutical APIS and intermediates. Our main products include Hormones, Anti-cancers,Antibiotic series.Antivirals and Custom manufacturing substances.Our strong products are Anti-cancer and Hormones.
During the past ten years, we have accumulated a wealth product knowledge and trading experience,established our own specialized selling network, have set up good relationship with the best Chinese producers in this field and represent some of the leading manufacturers,have trained a lot of high educated trading talented persons. Besides,we have jointly bulit up our own research and production base in Nanjing with 5 doctors from Nanjing University of Technology.
Our products have been exported to more than 30 countries,such as USA,Europe,Japan,Taiwan,HK,South East Asia,South American and Africa,etc.
At present, we are working in three main directions:
-As a marketing branch for several carefully selected manufacturing partners, which are GMP/FDA approved and mainly active in manufacturing Hormones&Oncology APIS.
-As a purchasing agent for several European companies in souring quality products from the right reliable manufacturers in China.
-As a trading company specialized in sourcing active pharmaceutical ingredients(APIS) and related advanced intermediates.
Quality of our products always complies with international standard,and well accepted by our customers and enjoyed a good reputation for the quality and competitive price in the world market.
Following is main products list(Pharm. API) of our company:
Hormones series: Budesonide ,Cyproterone Acetate, Finasteride, Hydrocortisone, Hydrocortisone Sodium Succinate, Medroxyprogesterone Acetate, Megestrol Acetate, Methylprednisolone, Mifepristone,Prednisolone Base, Progesterone, Dydrogesterone, Deflazacort.
Anti-cancers: Anastrozole, Bicalutamide, Busulfan,Capecitabine, Carboplatin, Cisplatin, Clofarabine,Cyclophosphamide, Cytarabine, Dacarbazine, Daunorubicin HCl, Dihydroartemisinin, Docetaxel,Doxorubicin HCl, Epirubicin HCL, Etoposide, Fludarabine, Gemcitabine, Ifosfamide, Imatinib Mesylate,Irinotecan，Letrozole, Leucovorin Calcium, Mesna, Methotrexate, Mitomycin C, Mitoxantrone HCl, Oxaliplatin, Paclitaxel, Tamoxifene Citrate, Teniposide, Topotecan, Vinblastine sulfate, Vincristine Sulphate, Vindesine Sulphate.
Antibiotics: Azithromycin, Biapenem, Bleomycin, Ciprofloxacin, Clarithromycin, Colistin sulphate, Cyclosprin A, Doxycycline HCL, Imipenem, Ivermectine, Lincomycin HCL, Meropenem, Neomycin sulphate, Rapamycin,Rifaximine, Tobramycin.
Antivirals: Aciclovir, Entecavir, Indinavir, Nelfinavir, Lamivudine, Oseltamivir Phosphate, Ribavirin,
Stavudine, Zidovudine.
Others: Acarbose, Amikacin Sulphate,Atracurium Besilate, Aztreonam, Benserazide HCl, Carvediol, Chlortetracycline HCL, Clindamycin HCL,Clopidogrel, Doxazosin Mesylate,Duloxetine HCL, Fluconazole, Fluoxetine HCL,Gemfibrozil, Gentamycin Sulphate ,Glimepiride,Glipizide, Granisetron HCI ,Idarubicin,Isotretinoin,Heparin Sodium, Itopride, Montelukast Sodium ,Orlistat, Pioglitazone,Pravastatin sodium, Ractopamine HCL,Risedronate sodium, Rosiglitazone Maleate,Rosuvastatin, Sibutramine,Sulbutiamine,Tegaserod Maleate, Telithromycin, Terazosin,Terbinafine, Tylosin Tartrate, Voglibose, Zonisamide.
Intermediates: Anastrozole,Atazanavir,Bicalutamide,Docetaxel, Ibandronate Sodiumn,Imipenem, Letrozole,Lopinavir,Meropenem,Ritonavir, Telithromycin Intermediates.
New Items: L-Leucovorin Calcium,Voriconazole,Lomustine,Enocitabine ,Clomifene Citrate,
6-Mercaptopurine,Amifostine,Trichlorosucrose,Cladribine,Sorafenib Tosylate, sunitinib malate,
Exenatide Acetate,Pramipexole Dihydrochloride,vatalanib dihydrochloride,Lonidamine,Triptorelin,Rubitecan.
Warmly we |
| Placement Date: |
Oct 10, 2006 |
| Expiration Date: |
Jan 01, 2010 |
|
